The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Open-label, phase II raptor study of everolimus (EVE) for papillary mRCC: Efficacy in type 1 and type 2 histology.
Bernard J. Escudier
Consultant or Advisory Role - Astellas Pharma; AVEO; Bayer-Schering; Genentech; GlaxoSmithKline; Novartis; Pfizer
Honoraria - AVEO; Bayer-Schering; Genentech; GlaxoSmithKline; Novartis; Pfizer
Sergio Bracarda
Consultant or Advisory Role - AVEO-Astellas; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Janssen; Novartis; Pfizer; Sanofi
José Pablo Maroto Rey
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer
Cezary Szczylik
Consultant or Advisory Role - AVEO; Bayer; Pfizer
Honoraria - Bayer; Pfizer
Paul D. Nathan
Consultant or Advisory Role - Novartis
Other Remuneration - Novartis
Sylvie Negrier
Honoraria - GlaxoSmithKline; Novartis; Pfizer
Research Funding - GlaxoSmithKline; Roche
Agnese Cattaneo
Employment or Leadership Position - Novartis
Claudia Weiss
Employment or Leadership Position - Novartis
Camillo Porta
Consultant or Advisory Role - Astellas Pharma; AVEO; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Novartis; Pfizer
Honoraria - Astellas Pharma; Bayer; GlaxoSmithKline; Novartis; Pfizer
Research Funding - Bayer; Novartis
Viktor Gruenwald
Consultant or Advisory Role - Astellas Pharma; Bayer; GlaxoSmithKline; Novartis; Pfizer; Roche